生益科技(600183.SH):全資孫公司咸陽地產擬投資開發公司舊址土地
格隆匯11月4日丨生益科技(600183.SH)公佈,2021年11月4日,公司召開第十屆董事會第十次會議,審議通過《關於全資孫公司咸陽生益房地產開發有限公司投資開發公司舊址土地的議案》,同意全資孫公司咸陽地產投資開發公司舊址土地,投資總額34.4690億元,為保證項目順利開展,授權公司管理層確定項目開發進度、銷售計劃及經營策略等事項。
投資標的名稱:生益金華1號(暫定名)(“該項目”)。該項目是公司通過咸陽地產實施,並且以向東莞地產增資的方式,向咸陽地產劃轉資金。公司投入15億元,咸陽地產投入19.4690億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.